MRC WIMM Spinouts
Since the Institute was founded in 1989, our researchers have successfully spun out a variety of different companies based on the science they developed here at the MRC WIMM.
A selection of these is highlighted below.
T-Cypher Bio (2021)
T-Cypher Bio emerged from Orbit Discovery to develop T-cell receptor-based therapeutics intended to provide a novel approach to cancer treatment.
![]() | MRC WIMM Founder: |
Yellowstone (2024)
Yellowstone Bioscience launched to pioneer new cancer treatments using advanced T-cell therapies, with an initial focus on acute myeloid leukaemia (AML).
![]() |
Eterna Biologics (2024)
Eterna Biologics is developing CRISPR-based RNA-targeting gene therapies to address a broad spectrum of diseases at the post-translational level.
![]() | Muhammad Hanifi & Daniel Fountain |
Singula Bio (2020)
Singula Bio aims to pioneer immunological, medical, surgical and computational technologies to generate selective therapies that eliminate cancer.
MRC WIMM Founders: the late Enzo Cerundolo Co-Founder: Enda McVeigh |
Alethiomics (2021)
Alethiomics aims to apply innovations in single cell multi-omic analysis to develop novel therapeutics for blood cancers.
MRC WIMM Founders: |
Nucleome Therapeutics (2022)
Nucleome fuses computational and biological expertise to understand how genes are regulated and interact in a dynamic multidimensional context, in order to decipher disease biology.
MRC WIMM Founders: Danuta Jeziorska |
TRex Bio (2018)
TRex Bio utilised single cell data from human tissue to build a discovery platform that maps Treg behaviour to disease. With this, they are developing therapies to treat inflammatory and autoimmune diseases.
![]() | MRC WIMM Founder: |
MiroBio (2019)
MiroBio was launched to develop novel therapeutics based on insights into receptor signalling in immune cells. The company was acquired by Gilead Sciences in 2022 for $405m.
![]() | MRC WIMM Founder: Co-Founder: Richard Cornall |
Dark Blue Therapeutics (2020)
Dark Blue Therapeutics is a pre-clinical biotech company tackling cancer with new therapies that target cancer cells' vulnerabilities and dependencies.
![]() | MRC WIMM Founders: & Nick Crump DBT co-founders (full list) |
Avidex (1999)
Avidex was founded in 1999, based on research by Bent's group at the (then) Institute of Molecular Medicine into the recognition of human leukocyte antigen (HLA) peptide antigens by T-cell receptors.
In 2006, the company was sold to MediGene. This TCR technology was further developed by Immunocore and Adaptimmune.
MRC WIMM Founder:
Bent Jakobsen
Adaptimmune & Immunocore (2008)
Adaptimmune was founded in 2008 and aims to discover and develop cell therapies to treat some of the most challenging solid tumours, utilising the patient's own immune system to combat the cancer.
Immunocore is a commercial-stage biotechnology company that discovered, developed and commercialized the world’s first approved T cell receptor (TCR) therapy. The company aims to develop medicines to improve outcomes for patients with cancer, infectious diseases, and autoimmune diseases.
MRC WIMM Founder:
Bent Jakobsen
Co-Founder: James Noble
Orbit Discovery (2015)
Orbit Discovery was launched to deploy a high-throughput peptide drug discovery platform to find both targeted binders and functional peptides for internal drug development and industry partnerships.
![]() | MRC WIMM Founders: & Terry Rabbits |